NeoGenomics, Inc. (NASDAQ: NEO) Stock Competitors & Peer Comparison
See NEO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NEO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NEO | $15.29 | -3.72% | 392.9M | 117.62 | $0.13 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.73% |
| TMO | $574.30 | -0.43% | 213.4B | 24.79 | $23.16 | +0.31% |
| DHR | $194.98 | -0.61% | 137.1B | 24.45 | $7.98 | +0.73% |
| IDXX | $559.07 | +0.05% | 44.1B | 41.17 | $13.58 | N/A |
| A | $138.37 | -0.25% | 39.1B | 23.82 | $5.81 | +0.73% |
| IQV | $235.02 | -1.16% | 38.7B | 19.38 | $12.13 | N/A |
| NTRA | $267.76 | -0.70% | 38.3B | -168.40 | -$1.59 | N/A |
| ILMN | $205.10 | +0.00% | 31B | 40.78 | $5.03 | N/A |
| MTD | $1,416.30 | +2.59% | 28.6B | 32.58 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
NEO vs DHR-PB Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, NEO's ROE is -0.06%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
NEO vs TMO Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, TMO has a market cap of 213.4B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while TMO trades at $574.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas TMO's P/E ratio is 24.79. In terms of profitability, NEO's ROE is -0.06%, compared to TMO's ROE of +0.13%. Regarding short-term risk, NEO is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for NEO.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
NEO vs DHR Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, DHR has a market cap of 137.1B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while DHR trades at $194.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas DHR's P/E ratio is 24.45. In terms of profitability, NEO's ROE is -0.06%, compared to DHR's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
NEO vs IDXX Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while IDXX trades at $559.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas IDXX's P/E ratio is 41.17. In terms of profitability, NEO's ROE is -0.06%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, NEO is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for NEO.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
NEO vs A Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, A has a market cap of 39.1B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while A trades at $138.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas A's P/E ratio is 23.82. In terms of profitability, NEO's ROE is -0.06%, compared to A's ROE of +0.21%. Regarding short-term risk, NEO is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for NEO.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
NEO vs IQV Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, IQV has a market cap of 38.7B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while IQV trades at $235.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas IQV's P/E ratio is 19.38. In terms of profitability, NEO's ROE is -0.06%, compared to IQV's ROE of +0.22%. Regarding short-term risk, NEO is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for NEO.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
NEO vs NTRA Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, NTRA has a market cap of 38.3B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while NTRA trades at $267.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas NTRA's P/E ratio is -168.40. In terms of profitability, NEO's ROE is -0.06%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, NEO is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NTRA's competition here
Illumina, Inc. (NASDAQ: ILMN)
NEO vs ILMN Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ILMN has a market cap of 31B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ILMN trades at $205.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ILMN's P/E ratio is 40.78. In terms of profitability, NEO's ROE is -0.06%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, NEO is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
NEO vs MTD Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, MTD has a market cap of 28.6B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while MTD trades at $1,416.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas MTD's P/E ratio is 32.58. In terms of profitability, NEO's ROE is -0.06%, compared to MTD's ROE of -12.00%. Regarding short-term risk, NEO is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
NEO vs DGX Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while DGX trades at $233.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas DGX's P/E ratio is 22.98. In terms of profitability, NEO's ROE is -0.06%, compared to DGX's ROE of +0.14%. Regarding short-term risk, NEO is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
NEO vs LH Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while LH trades at $309.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas LH's P/E ratio is 18.36. In terms of profitability, NEO's ROE is -0.06%, compared to LH's ROE of +0.12%. Regarding short-term risk, NEO is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check LH's competition here
Waters Corporation (NYSE: WAT)
NEO vs WAT Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, WAT has a market cap of 24.6B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while WAT trades at $377.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas WAT's P/E ratio is 27.78. In terms of profitability, NEO's ROE is -0.06%, compared to WAT's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for NEO.Check WAT's competition here
Guardant Health, Inc. (NASDAQ: GH)
NEO vs GH Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, GH has a market cap of 21.5B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while GH trades at $161.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas GH's P/E ratio is -62.79. In terms of profitability, NEO's ROE is -0.06%, compared to GH's ROE of +2.11%. Regarding short-term risk, NEO is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for NEO.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
NEO vs EXAS Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas EXAS's P/E ratio is -95.37. In terms of profitability, NEO's ROE is -0.06%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, NEO is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for NEO.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
NEO vs ILMNV Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ILMNV's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to ILMNV's ROE of N/A. Regarding short-term risk, NEO is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for NEO.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
NEO vs MEDP Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, MEDP has a market cap of 16.1B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while MEDP trades at $577.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas MEDP's P/E ratio is 36.27. In terms of profitability, NEO's ROE is -0.06%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, NEO is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for NEO.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
NEO vs PKI Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas PKI's P/E ratio is 41.45. In terms of profitability, NEO's ROE is -0.06%, compared to PKI's ROE of +0.03%. Regarding short-term risk, NEO is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
NEO vs RVTY Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, RVTY has a market cap of 12.6B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while RVTY trades at $112.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas RVTY's P/E ratio is 21.98. In terms of profitability, NEO's ROE is -0.06%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, NEO is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for NEO.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
NEO vs ICLR Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ICLR has a market cap of 12.5B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ICLR trades at $163.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ICLR's P/E ratio is 13.34. In terms of profitability, NEO's ROE is -0.06%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, NEO is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
NEO vs CRL Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CRL has a market cap of 11.2B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CRL trades at $232.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CRL's P/E ratio is 23.25. In terms of profitability, NEO's ROE is -0.06%, compared to CRL's ROE of -0.06%. Regarding short-term risk, NEO is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for NEO.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
NEO vs QGEN Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while QGEN trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas QGEN's P/E ratio is 17.25. In terms of profitability, NEO's ROE is -0.06%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, NEO is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for NEO.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
NEO vs BLLN Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, BLLN has a market cap of 6.4B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while BLLN trades at $138.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas BLLN's P/E ratio is 252.00. In terms of profitability, NEO's ROE is -0.06%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for NEO.Check BLLN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
NEO vs TWST Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, TWST has a market cap of 5.7B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while TWST trades at $91.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas TWST's P/E ratio is -42.98. In terms of profitability, NEO's ROE is -0.06%, compared to TWST's ROE of -0.17%. Regarding short-term risk, NEO is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for NEO.Check TWST's competition here
Sotera Health Company (NASDAQ: SHC)
NEO vs SHC Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, SHC has a market cap of 5.1B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while SHC trades at $17.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas SHC's P/E ratio is 19.84. In terms of profitability, NEO's ROE is -0.06%, compared to SHC's ROE of +0.21%. Regarding short-term risk, NEO is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for NEO.Check SHC's competition here
RadNet, Inc. (NASDAQ: RDNT)
NEO vs RDNT Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, RDNT has a market cap of 5B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while RDNT trades at $63.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas RDNT's P/E ratio is 138.65. In terms of profitability, NEO's ROE is -0.06%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, NEO is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for NEO.Check RDNT's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
NEO vs SYNH Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas SYNH's P/E ratio is 61.40. In terms of profitability, NEO's ROE is -0.06%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
NEO vs VCYT Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while VCYT trades at $46.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas VCYT's P/E ratio is 23.16. In terms of profitability, NEO's ROE is -0.06%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, NEO is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for NEO.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
NEO vs OLK Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas OLK's P/E ratio is -96.59. In terms of profitability, NEO's ROE is -0.06%, compared to OLK's ROE of -0.07%. Regarding short-term risk, NEO is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for NEO.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
NEO vs NEOG Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while NEOG trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas NEOG's P/E ratio is 43.00. In terms of profitability, NEO's ROE is -0.06%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, NEO is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NEOG's competition here
CareDx, Inc (NASDAQ: CDNA)
NEO vs CDNA Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CDNA has a market cap of 2.3B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CDNA trades at $43.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CDNA's P/E ratio is 52.04. In terms of profitability, NEO's ROE is -0.06%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, NEO is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
NEO vs PSNL Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, PSNL has a market cap of 1.4B. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while PSNL trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas PSNL's P/E ratio is -12.41. In terms of profitability, NEO's ROE is -0.06%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, NEO is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for NEO.Check PSNL's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
NEO vs CSTL Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CSTL has a market cap of 849.2M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CSTL trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CSTL's P/E ratio is -63.64. In terms of profitability, NEO's ROE is -0.06%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, NEO is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
NEO vs GRALV Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas GRALV's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to GRALV's ROE of N/A. Regarding short-term risk, NEO is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for NEO.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
NEO vs FLGT Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, FLGT has a market cap of 470M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while FLGT trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas FLGT's P/E ratio is 1655.00. In terms of profitability, NEO's ROE is -0.06%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, NEO is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for NEO.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
NEO vs CO Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CO's P/E ratio is 5.06. In terms of profitability, NEO's ROE is -0.06%, compared to CO's ROE of +0.11%. Regarding short-term risk, NEO is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CO's competition here
Prenetics Global Limited (NASDAQ: PRENW)
NEO vs PRENW Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, PRENW has a market cap of 360.8M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas PRENW's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, NEO is more volatile compared to PRENW. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PRENW's competition here
Prenetics Global Limited (NASDAQ: PRE)
NEO vs PRE Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, PRE has a market cap of 316.9M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while PRE trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas PRE's P/E ratio is -9.05. In terms of profitability, NEO's ROE is -0.06%, compared to PRE's ROE of -0.47%. Regarding short-term risk, NEO is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for NEO.Check PRE's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
NEO vs FLDM Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas FLDM's P/E ratio is -4.74. In terms of profitability, NEO's ROE is -0.06%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, NEO is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for NEO.Check FLDM's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
NEO vs MYGN Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, MYGN has a market cap of 270.1M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while MYGN trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas MYGN's P/E ratio is -22.00. In terms of profitability, NEO's ROE is -0.06%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, NEO is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MYGN's competition here
Trinity Biotech plc (NASDAQ: TRIB)
NEO vs TRIB Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, TRIB has a market cap of 234.9M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while TRIB trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas TRIB's P/E ratio is -3.01. In terms of profitability, NEO's ROE is -0.06%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, NEO is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for NEO.Check TRIB's competition here
Biodesix, Inc. (NASDAQ: BDSX)
NEO vs BDSX Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, BDSX has a market cap of 172.6M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while BDSX trades at $21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas BDSX's P/E ratio is -5.22. In terms of profitability, NEO's ROE is -0.06%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, NEO is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BDSX's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
NEO vs IMDX Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, IMDX has a market cap of 150.1M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while IMDX trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas IMDX's P/E ratio is -3.91. In terms of profitability, NEO's ROE is -0.06%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, NEO is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for NEO.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
NEO vs GTH Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas GTH's P/E ratio is -1.11. In terms of profitability, NEO's ROE is -0.06%, compared to GTH's ROE of -1.01%. Regarding short-term risk, NEO is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
NEO vs GENE Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas GENE's P/E ratio is -38.25. In terms of profitability, NEO's ROE is -0.06%, compared to GENE's ROE of -1.85%. Regarding short-term risk, NEO is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for NEO.Check GENE's competition here
Exagen Inc. (NASDAQ: XGN)
NEO vs XGN Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, XGN has a market cap of 109.4M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while XGN trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas XGN's P/E ratio is -6.12. In terms of profitability, NEO's ROE is -0.06%, compared to XGN's ROE of -1.14%. Regarding short-term risk, NEO is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for NEO.Check XGN's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
NEO vs SERA Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, SERA has a market cap of 79.8M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas SERA's P/E ratio is -3.22. In terms of profitability, NEO's ROE is -0.06%, compared to SERA's ROE of -0.41%. Regarding short-term risk, NEO is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check SERA's competition here
Atlantic International Corp. (NASDAQ: ATLN)
NEO vs ATLN Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ATLN's P/E ratio is -0.68. In terms of profitability, NEO's ROE is -0.06%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, NEO is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ATLN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
NEO vs DRIO Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, DRIO has a market cap of 53.2M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while DRIO trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas DRIO's P/E ratio is -1.24. In terms of profitability, NEO's ROE is -0.06%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, NEO is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for NEO.Check DRIO's competition here
Precipio, Inc. (NASDAQ: PRPO)
NEO vs PRPO Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, PRPO has a market cap of 38.7M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while PRPO trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas PRPO's P/E ratio is -83.27. In terms of profitability, NEO's ROE is -0.06%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, NEO is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for NEO.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
NEO vs AKU Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas AKU's P/E ratio is -0.13. In terms of profitability, NEO's ROE is -0.06%, compared to AKU's ROE of -5.32%. Regarding short-term risk, NEO is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for NEO.Check AKU's competition here
MDxHealth S.A. (NASDAQ: MDXH)
NEO vs MDXH Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, MDXH has a market cap of 21.5M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while MDXH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas MDXH's P/E ratio is -1.10. In terms of profitability, NEO's ROE is -0.06%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, NEO is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
NEO vs CEMI Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CEMI's P/E ratio is -0.63. In terms of profitability, NEO's ROE is -0.06%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, NEO is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for NEO.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
NEO vs ENZ Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ENZ's P/E ratio is -2.24. In terms of profitability, NEO's ROE is -0.06%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, NEO is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
NEO vs PMD Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas PMD's P/E ratio is -5.24. In terms of profitability, NEO's ROE is -0.06%, compared to PMD's ROE of -0.32%. Regarding short-term risk, NEO is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
NEO vs ME Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ME's P/E ratio is -0.03. In terms of profitability, NEO's ROE is -0.06%, compared to ME's ROE of -42.03%. Regarding short-term risk, NEO is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for NEO.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
NEO vs MYNZ Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, NEO's ROE is -0.06%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, NEO is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MYNZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
NEO vs QUCY Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, QUCY has a market cap of 14.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while QUCY trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas QUCY's P/E ratio is -0.05. In terms of profitability, NEO's ROE is -0.06%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, NEO is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for NEO.Check QUCY's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
NEO vs BNGO Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, BNGO has a market cap of 12.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while BNGO trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas BNGO's P/E ratio is -0.24. In terms of profitability, NEO's ROE is -0.06%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, NEO is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BNGO's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
NEO vs CHEK Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CHEK's P/E ratio is -0.43. In terms of profitability, NEO's ROE is -0.06%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, NEO is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
NEO vs CNTG Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CNTG's P/E ratio is -0.23. In terms of profitability, NEO's ROE is -0.06%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, NEO is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for NEO.Check CNTG's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
NEO vs BNR Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, BNR has a market cap of 9.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while BNR trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas BNR's P/E ratio is -10.73. In terms of profitability, NEO's ROE is -0.06%, compared to BNR's ROE of -0.11%. Regarding short-term risk, NEO is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for NEO.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
NEO vs ADVB Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ADVB trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ADVB's P/E ratio is -72.73. In terms of profitability, NEO's ROE is -0.06%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, NEO is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ADVB's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
NEO vs MBAI Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, MBAI has a market cap of 7.4M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while MBAI trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas MBAI's P/E ratio is 1.58. In terms of profitability, NEO's ROE is -0.06%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, NEO is less volatile compared to MBAI. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
NEO vs APDN Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas APDN's P/E ratio is -0.10. In terms of profitability, NEO's ROE is -0.06%, compared to APDN's ROE of -6.53%. Regarding short-term risk, NEO is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for NEO.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
NEO vs NVTA Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas NVTA's P/E ratio is -0.00. In terms of profitability, NEO's ROE is -0.06%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, NEO is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
NEO vs LMDX Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas LMDX's P/E ratio is -0.01. In terms of profitability, NEO's ROE is -0.06%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, NEO is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for NEO.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
NEO vs LMDXW Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, NEO's ROE is -0.06%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, NEO is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check LMDXW's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
NEO vs NDRA Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, NDRA has a market cap of 3.6M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while NDRA trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas NDRA's P/E ratio is -0.61. In terms of profitability, NEO's ROE is -0.06%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, NEO is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NDRA's competition here
DermTech, Inc. (NASDAQ: DMTK)
NEO vs DMTK Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas DMTK's P/E ratio is -0.04. In terms of profitability, NEO's ROE is -0.06%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, NEO is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for NEO.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
NEO vs BIAF Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, BIAF has a market cap of 2.8M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while BIAF trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas BIAF's P/E ratio is -0.07. In terms of profitability, NEO's ROE is -0.06%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, NEO is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
NEO vs NOTV Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas NOTV's P/E ratio is -0.03. In terms of profitability, NEO's ROE is -0.06%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, NEO is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
NEO vs SQL Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas SQL's P/E ratio is -0.40. In terms of profitability, NEO's ROE is -0.06%, compared to SQL's ROE of +38.02%. Regarding short-term risk, NEO is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for NEO.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
NEO vs AWH Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas AWH's P/E ratio is -0.09. In terms of profitability, NEO's ROE is -0.06%, compared to AWH's ROE of +2.03%. Regarding short-term risk, NEO is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for NEO.Check AWH's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
NEO vs INBS Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, INBS has a market cap of 1.2M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while INBS trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas INBS's P/E ratio is -0.21. In terms of profitability, NEO's ROE is -0.06%, compared to INBS's ROE of -1.74%. Regarding short-term risk, NEO is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for NEO.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
NEO vs HTGM Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas HTGM's P/E ratio is -0.03. In terms of profitability, NEO's ROE is -0.06%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, NEO is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for NEO.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
NEO vs BIOC Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas BIOC's P/E ratio is -0.01. In terms of profitability, NEO's ROE is -0.06%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, NEO is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
NEO vs ISPC Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, ISPC has a market cap of 262.4K. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while ISPC trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas ISPC's P/E ratio is -0.06. In terms of profitability, NEO's ROE is -0.06%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, NEO is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for NEO.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
NEO vs SQLLW Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, NEO's ROE is -0.06%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, NEO is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check SQLLW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
NEO vs BNGOW Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas BNGOW's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, NEO is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
NEO vs CHEKZ Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, NEO is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for NEO.Check CHEKZ's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
NEO vs NDRAW Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas NDRAW's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, NEO is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
NEO vs MEUSW Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas MEUSW's P/E ratio is N/A. In terms of profitability, NEO's ROE is -0.06%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, NEO is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for NEO.Check MEUSW's competition here
Danaher Corporation (NYSE: DHR-PA)
NEO vs DHR-PA Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, NEO's ROE is -0.06%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, NEO is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for NEO.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
NEO vs PRXL Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas PRXL's P/E ratio is 42.97. In terms of profitability, NEO's ROE is -0.06%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, NEO is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for NEO.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
NEO vs OCDX Comparison August 2026
NeoGenomics, Inc. (NASDAQ: NEO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEO stands at 392.9M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, NEO is priced at $15.29 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEO currently has a P/E ratio of 117.62, whereas OCDX's P/E ratio is -42.28. In terms of profitability, NEO's ROE is -0.06%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, NEO is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for NEO.Check OCDX's competition here